Literature DB >> 23602875

Molecular basis of cross-species reactivities of human versus porcine CTLA-4.

Jaclyn Stromp Peraino1, Huiping Zhang, Guoying Li, Christene A Huang, Zhirui Wang.   

Abstract

The binding motif of human CTLA-4 is well known to be MYPPPY and for porcine CTLA-4 the binding motif is LYPPPY. Is this single amino acid difference of methionine (M) versus leucine (L) critical for the CTLA-4 binding? Recently, we have reported that the recombinant soluble porcine CTLA-4 was incapable of binding to human CD80. In this study we mutated L to M in the binding motif of the soluble porcine CTLA-4 and mutated M to L in the binding motif of the soluble human CTLA-4. We then analyzed how these mutations affected the binding affinity of the mutants to both porcine and human CD80(+) cells. The soluble porcine CTLA-4-L97M mutant partially lost its binding affinity to porcine CD80 compared to the wild-type and conferred very weak binding ability to human CD80. These results indicate that the L in the binding motif of porcine CTLA-4 is important for determining its binding ability to porcine CD80. Wild-type soluble human CTLA-4 binds to both human and porcine CD80 with comparable affinity, however, the soluble human CTLA-4-M97L mutant almost lost its binding ability to human CD80 and increased its binding ability to porcine CD80. These results indicate that M in the human CTLA-4 binding motif is extremely critical for its binding to human CD80. Those data suggest that the human CTLA-4 based recombinant protein drugs such as human CTLA-4-Ig can be used and/or tested in a porcine model. Conversely, the use of porcine CTLA-4 based recombinant protein drugs such as porcine CTLA-4-Ig is restricted to swine models. The difference in binding specificity of CTLA-4 observed in this study may be useful for studies such as pig to nonhuman primate xeno-transplantation. Porcine CTLA-4- and human CTLA-4-M97L mutant-based recombinant protein drugs can be used to specifically block the direct presentation by donor antigen presenting cells in pig to nonhuman primate xeno-transplantation. Human CTLA-4-M97L mutant-based recombinant protein drugs will be more ideal as it is without immunogenicity to human being.
Copyright © 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23602875      PMCID: PMC3721328          DOI: 10.1016/j.humimm.2013.04.002

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  10 in total

Review 1.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

2.  B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse.

Authors:  Tsvetelina Pentcheva-Hoang; Jackson G Egen; Kathleen Wojnoonski; James P Allison
Journal:  Immunity       Date:  2004-09       Impact factor: 31.745

3.  B7-independent inhibition of T cells by CTLA-4.

Authors:  Shunsuke Chikuma; Abul K Abbas; Jeffrey A Bluestone
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

4.  CD28 co-signaling in the adaptive immune response.

Authors:  Pavel Riha; Christopher E Rudd
Journal:  Self Nonself       Date:  2010-07-12

Review 5.  Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.

Authors:  Hélène Bour-Jordan; Jonathan H Esensten; Marc Martinez-Llordella; Cristina Penaranda; Melanie Stumpf; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

6.  Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2).

Authors:  P A Morton; X T Fu; J A Stewart; K S Giacoletto; S L White; C E Leysath; R J Evans; J J Shieh; R W Karr
Journal:  J Immunol       Date:  1996-02-01       Impact factor: 5.422

7.  Porcine CTLA4-Ig lacks a MYPPPY motif, binds inefficiently to human B7 and specifically suppresses human CD4+ T cell responses costimulated by pig but not human B7.

Authors:  A N Vaughan; P Malde; N J Rogers; I M Jackson; R I Lechler; A Dorling
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

8.  Expression and characterization of recombinant soluble porcine CD3 ectodomain molecules: mapping the epitope of an anti-porcine CD3 monoclonal antibody 898H2-6-15.

Authors:  Jaclyn Stromp Peraino; Christina E Hermanrud; Lauren Springett; Huiping Zhang; Guoying Li; Srimathi Srinivasan; Ashley Gusha; David H Sachs; Christene A Huang; Zhirui Wang
Journal:  Cell Immunol       Date:  2012-05-18       Impact factor: 4.868

9.  Expression and purification of soluble porcine CTLA-4 in yeast Pichia pastoris.

Authors:  Jaclyn Peraino; Huiping Zhang; Christina E Hermanrud; Guoying Li; David H Sachs; Christene A Huang; Zhirui Wang
Journal:  Protein Expr Purif       Date:  2012-02-02       Impact factor: 1.650

10.  Establishment of transplantable porcine tumor cell lines derived from MHC-inbred miniature swine.

Authors:  Patricia S Cho; Diana P Lo; Krzysztof J Wikiel; Haley C Rowland; Rebecca C Coburn; Isabel M McMorrow; Jennifer G Goodrich; J Scott Arn; Robert A Billiter; Stuart L Houser; Akira Shimizu; Yong-Guang Yang; David H Sachs; Christene A Huang
Journal:  Blood       Date:  2007-08-16       Impact factor: 22.113

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.